COMPOUND PROFILE / PEPTIDES & ANALOGUES
CJC-1295 No DAC / Mod GRF 1-29.
Research draftCJC-1295 No DAC is a market name commonly used for modified GRF 1-29.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Identity and evidence review notes
Confirm exact identity, sequence, alias or formulation before attaching product-specific evidence.
No matched primary reference supports a therapeutic claim in this content pass. Retain the evidence gap; do not substitute seller claims.
Overview
CJC-1295 No DAC is a market name commonly used for modified GRF 1-29.
Mechanism
This shorter-acting GHRH analogue stimulates pituitary growth-hormone release without the albumin-binding DAC extension.
Human research
Studies of long-acting CJC-1295 cannot be attributed to this preparation. A strong direct clinical evidence base for current wellness products was not identified.
Preclinical & other research
General GHRH biology provides a rationale, but exact sequence and formulation matter.
Safety & unknowns
Hormonal effects, glucose changes and product quality require consideration; reliable long-term safety data are lacking.
Regulatory status
Identity must be checked against the sequence on the report; no wellness-use approval is established.
Reported use & evidence
The supplied CJC-1295 No DAC / Mod GRF 1-29 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.